| (Values in U.S. Thousands) | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 | Jun, 2021 |
| Sales | 27,530 | 8,700 | 11,590 | 5,200 | 13,010 |
| Sales Growth | +216.44% | -24.94% | +122.88% | -60.03% | +70.51% |
| Net Income | -35,740 | -55,510 | -50,650 | -65,830 | -64,360 |
| Net Income Growth | +35.62% | -9.60% | +23.06% | -2.28% | +8.41% |
Epizyme Inc (EPZM)
Epizyme Inc (EPZM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
Fiscal Year End Date: 12/31